NCT00510653View on ClinicalTrials.gov

Gleevec Study for Patients With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Ovarian Cancer
Interventions
DRUG

Imatinib Mesylate

600 mg by mouth daily for 6 Weeks

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00510653 - Gleevec Study for Patients With Ovarian Cancer | Biotech Hunter | Biotech Hunter